Last10K.com

Abbott Laboratories (ABT) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2012

Abbott Laboratories

CIK: 1800 Ticker: ABT

Exhibit 99.1

 

 

 

Abbott Reports Fourth-Quarter and Full-Year 2012 Results

 

 

 

 

 

– Fourth-Quarter Ongoing EPS of $1.51 (GAAP EPS of $0.66)

Full-Year Ongoing EPS of $5.07 (GAAP EPS of $3.72)

Abbott Contacts:

 

Completed Launch of AbbVie, a New Biopharmaceutical Company

 

 

Company Issues Strong Earnings Outlook for 2013

Financial:

 

 

Brian Yoor

(847) 937-6343

 

Tina Ventura

(847) 935-9390

 

Media:

Melissa Brotz

(847) 935-3456

 

Scott Stoffel

(847) 936-9502

 

AbbVie Contacts:

 

Financial:

Larry Peepo

(847) 935-6722

 

Media:

Adelle Infante

(847) 938-8745

 

ABBOTT PARK, Ill., Jan. 23, 2013 — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2012.

 

·                  Fourth-quarter diluted earnings per share, excluding specified items, were $1.51. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.66, including specified items.

 

·                  Full-year diluted earnings per share, excluding specified items, were $5.07, exceeding Abbott’s initial guidance range. Diluted earnings per share under GAAP were $3.72, including specified items.

 

·                  Excluding foreign exchange, worldwide sales increased 5.6 percent. Reported sales increased 4.4 percent, including an unfavorable 1.2 percent effect of foreign exchange.

 

·                  On Jan. 1, 2013, Abbott completed the launch of AbbVie, a new research-based biopharmaceutical company.

 

·                  Abbott launched numerous new products across its diversified businesses in 2012, positioning the company well for future growth. Key pipeline innovations include the launch of its Absorb bioresorbable vascular scaffold; the next-generation drug-eluting stent, XIENCE Xpedition; 80 launches across its Nutrition business; new tests in Diagnostics; as well as several new product and geographic expansion initiatives in Established Pharmaceuticals, Diabetes Care and Vision Care.

 

“In 2012, we achieved a significant milestone in Abbott’s 125-year history with the creation of AbbVie while delivering another year of strong results,” said Miles D. White, chairman and chief executive officer, Abbott. “Abbott’s mix of diversified healthcare businesses and pipeline is favorably aligned with key healthcare and emerging market trends, and well positioned to deliver top-tier growth in 2013.”

 


The following information was filed by Abbott Laboratories (ABT) on Wednesday, January 23, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Abbott Laboratories's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abbott Laboratories.

Continue

Assess how Abbott Laboratories's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abbott Laboratories's Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheet
Consolidated Balance Sheet (parenthetical)
Consolidated Statement Of Cash Flows
Consolidated Statement Of Comprehensive Income
Consolidated Statement Of Comprehensive Income (parenthetical)
Consolidated Statement Of Earnings
Consolidated Statement Of Shareholders' Investment
Consolidated Statement Of Shareholders' Investment (parenthetical)
Business Combinations, Technology Acquisitions And Related Transactions
Business Combinations, Technology Acquisitions And Related Transactions (details)
Debt And Lines Of Credit
Debt And Lines Of Credit (details)
Debt And Lines Of Credit (tables)
Financial Instruments, Derivatives And Fair Value Measures
Financial Instruments, Derivatives And Fair Value Measures (details 2)
Financial Instruments, Derivatives And Fair Value Measures (details 3)
Financial Instruments, Derivatives And Fair Value Measures (details 4)
Financial Instruments, Derivatives And Fair Value Measures (details)
Financial Instruments, Derivatives And Fair Value Measures (tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (details)
Incentive Stock Program
Incentive Stock Programs (details)
Incentive Stock Programs (tables)
Litigation And Environmental Matters
Litigation And Environmental Matters (details)
Post-employment Benefits
Post-employment Benefits (details 2)
Post-employment Benefits (details)
Post-employment Benefits (tables)
Quarterly Results (unaudited)
Quarterly Results (unaudited) (details)
Quarterly Results (unaudited) (tables)
Restructuring Plans
Restructuring Plans (details)
Restructuring Plans (tables)
Schedule Ii Valuation And Qualifying Accounts
Schedule Ii Valuation And Qualifying Accounts (details)
Segment And Geographic Area Information
Segment And Geographic Area Information (details 2)
Segment And Geographic Area Information (details 3)
Segment And Geographic Area Information (details)
Segment And Geographic Area Information (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details 2)
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Supplemental Financial Information
Supplemental Financial Information (details)
Supplemental Financial Information (tables)
Taxes On Earnings
Taxes On Earnings (details 2)
Taxes On Earnings (details)
Taxes On Earnings (tables)
Ticker: ABT
CIK: 1800
Form Type: 10-K Annual Report
Accession Number: 0001047469-13-001180
Submitted to the SEC: Fri Feb 15 2013 3:15:07 PM EST
Accepted by the SEC: Fri Feb 15 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/abt/0001047469-13-001180.htm